<DOC>
	<DOC>NCT00171119</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.</brief_summary>
	<brief_title>A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>male or female patients aged 3575 years with type 2 diabetes mellitus and recent evidence of persistent microalbuminuria patients with a median (of 3 samples) timed overnight UAER in the microalbuminuric range of 20200 g/min in the formal screening period prior to entry patients who give written, signed, informed consent. patients with/without mild /moderate hypertension. patients who are not on hypertensive treatment, or if they are already on treatment, those who accept to enter a 3 weeks notreatment washout period before switching their treatment. patients without any accompanying systemic disease pregnant or nursing women, or women of childbearing potential not using an acceptable method of contraception patients with type I diabetes mellitus defined by onset below the age of 35 years and requiring insulin within the first year after diagnosis Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>HYPERTENSION</keyword>
	<keyword>DIABETES MELLITUS TYPE II</keyword>
	<keyword>VALSARTAN</keyword>
	<keyword>BENAZAPRIL</keyword>
</DOC>